succinamide

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2017 - "Succinamide analogs 3a, 3c-3l and 4b-4h were also evaluated for their apoptotic activity against M9-ENL1 acute myelogenous leukemia cells; compounds 3h-3j and 4g were equipotent with parthenolide, exhibiting LC50 values in the range 4.1-8.1μM. "
2.	Pain (Aches) 08/03/2004 - "A disubstituted succinamide is a potent sodium channel blocker with efficacy in a rat pain model."
3.	Neoplasms (Cancer) 01/01/2017 - "These succinamide analogs of MMB were evaluated for their anti-cancer activity against a panel of sixty human cancer cell lines. " 01/01/2017 - "Succinamide derivatives of melampomagnolide B and their anti-cancer activities."
4.	Bradycardia 09/01/1997 - "A series of succinamide derivatives containing the 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one skeleton (6a-z) was prepared and evaluated for binding affinity to muscarinic receptors in vitro and for antagonism of bradycardia and salivation in vivo in comparison with AF-DX 116 (1a). "
5.	Neuroinflammatory Diseases 01/01/2020 - "Succinamide Derivatives Ameliorate Neuroinflammation and Oxidative Stress in Scopolamine-Induced Neurodegeneration."

1.	Sodium Channel Blockers
2.	Ethylene Glycol (Monoethylene Glycol)
3.	Scopolamine (Hyoscine)
4.	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
5.	Lysine (L-Lysine)
6.	melampomagnolide B
7.	otenzepad
8.	phosphorylethanolamine (phosphoethanolamine)
9.	parthenolide